Doxiproct 40 mg/20 mg/g ointment Búlgaría - búlgarska - Изпълнителна агенция по лекарствата

doxiproct 40 mg/20 mg/g ointment

om pharma s.a. - лидокаин хидрохлорид, монохидрат довязывать калций - 40 mg/20 mg/g ointment

Доксипрокт Плюс 40 mg/20 mg/0,25 mg/g маз - 20g Búlgaría - búlgarska - Изпълнителна агенция по лекарствата

Доксипрокт Плюс 40 mg/20 mg/0,25 mg/g маз - 20g

om pharma s.a. - лидокаин хидрохлорид, монохидрат довязывать калций, дексаметазон ацетат -

Doxium 500 mg capsules, hard Búlgaría - búlgarska - Изпълнителна агенция по лекарствата

doxium 500 mg capsules, hard

om pharma s.a. - Довязывать калций - 500 mg capsules, hard

Sutent Evrópusambandið - búlgarska - EMA (European Medicines Agency)

sutent

pfizer limited - сунитиниб - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - Антинеопластични средства - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.